Trends in GLP-1 RA Prescriptions: Implications for Metabolic Health

The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has gained attention in recent years as a significant treatment option for individuals with type 2 diabetes mellitus (T2D) and those struggling with obesity. As metabolic health continues to be a pressing public health concern, understanding the prescribing trends of GLP-1 RAs is essential for both healthcare providers and patients. This analysis utilizes real-world electronic health record data to provide insights into the current landscape of GLP-1 RA prescriptions in the United States, revealing important trends that could impact metabolic health management. Between January 2019 and December 2025, over 2.1 million patients were prescribed GLP-1 RAs, totaling more than 11 million prescriptions. Notably, 69.1% of these prescriptions were for anti-diabetic medications (ADMs), while 30.9% were for anti-obesity medications (AOMs). Despite a slight increase in overall prescribing rates of GLP-1 RAs by 5.02% from September to December 2025, first-time prescribing rates saw a decline of 6.62%. By the end of 2025, GLP-1 RA prescriptions accounted for over 7% of all prescriptions, indicating a growing acceptance of these medications in clinical practice. For individuals managing metabolic health, these trends underscore the importance of GLP-1 RAs as a viable treatment option. Patients with T2D or obesity may benefit from discussing GLP-1 RA options with their healthcare providers, especially given the dual role these medications play in managing blood glucose levels and aiding weight loss. Understanding the characteristics of patients receiving these prescriptions can also help tailor treatment plans to individual needs, enhancing overall metabolic health outcomes. In terms of biomarkers, GLP-1 RAs can positively influence several metabolic indicators. For instance, they can help lower fasting insulin and glucose levels, which are critical markers for insulin resistance. Additionally, improvements in lipid profiles, including reductions in triglycerides and increases in HDL cholesterol, can be observed with effective GLP-1 RA therapy. These changes are essential for assessing metabolic syndrome and overall cardiovascular health. In conclusion, the rising trend in GLP-1 RA prescriptions reflects a significant shift in the management of T2D and obesity, with potential benefits for metabolic health. Patients should consider discussing these treatment options with their healthcare providers to explore how GLP-1 RAs may fit into their health journey. As the landscape of diabetes and obesity treatment continues to evolve, staying informed about these developments is crucial for optimizing metabolic health.